SCHEMBL879

SCHEMBL879

C[C@@]1(O)CCOC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331223 1.00
SCHEMBL880 1.00
SCHEMBL22905077 1.00
Water SCHEMBL23042868 0.98 LMNA (0.96)
Water SCHEMBL23042869 0.98 LMNA (0.96)
SCHEMBL28787742 0.87 LMNA (0.76)
Imidazole SCHEMBL28835236 0.79 LMNA (0.63)
SCHEMBL6555571 0.76
SCHEMBL15856528 0.76
SCHEMBL438928 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9455 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
WO-2026088246-A1 METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND NTT株式会社 2026-04-30 WO claimed
EP-4296365-B1 PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID VISOLIS INC (US) 2026-04-15 EP claimed
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-04-02 US claimed
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-04-02 US claimed
EP-4706822-A2 METHODS FOR RECOVERING ORGANIC ACIDS OR SALTS OR LACTONES THEREOF FROM AQUEOUS SOLUTIONS USING WATER SOLVENT CRYSTALLIZATION AND COMPOSITIONS THEREOF Danisco US Inc. (US) 2026-03-11 EP claimed
US-20260028433-A1 PROCESS FOR SYNTHESIZING TACKIFYING COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-01-29 US claimed
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM VISOLIS INC (US) 2026-01-29 US claimed
US-12503421-B2 Methods for recovering organic acids or salts or lactones thereof from aqueous solutions using water solvent crystallization and compositions thereof DANISCO US INC. (US) 2025-12-23 US claimed
EP-4357386-B1 POLY(3-HYDROXYPROPIONIC ACID) BLOCK COPOLYMER, MANUFACTURING METHOD THEREOF AND PRODUCTS CONTAINING THE SAME LG CHEMICAL LTD (KR) 2025-10-29 EP claimed
EP-0508665-A2 Use of ACE inhibitors for lowering serum cholesterol E.R. SQUIBB &amp; SONS, INC. (US) 1992-10-14 EP claimed
US-5149835-A Substituted mevalonolactones, and methods for stereoselective preparation thereof and desmethyl homologues thereof UNIVERSITY OF NEW MEXICO (US) 1992-09-22 US claimed
EP-0482498-A2 Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor E.R. SQUIBB &amp; SONS, INC. (US) 1992-04-29 EP claimed
EP-0461548-A2 Method for preventing a second heart attack employing and HMG CoA reductase inhibitor E.R. SQUIBB &amp; SONS, INC. (US) 1991-12-18 EP claimed
EP-0457514-A1 Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor E.R. SQUIBB &amp; SONS, INC. (US) 1991-11-21 EP claimed
EP-0401705-A2 Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease E.R. Squibb &amp; Sons, Inc. (US) 1990-12-12 EP claimed
EP-0373507-A1 Combination of an HMG CoA reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination E.R. SQUIBB &amp; SONS, INC. (US) 1990-06-20 EP claimed
EP-0170933-B1 GAMMA-AMINOBUTYRIC ACID DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS KURARAY CO., LTD. (JP) 1988-08-31 EP claimed
EP-0060565-B1 FULLY SYNTHETIC CELL CULTURE MEDIUM Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1986-06-25 EP claimed
EP-0060565-A2 Fully synthetic cell culture medium Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1982-09-22 EP claimed